Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 6,604 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Proteinuria
Interventions: Belatacept; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Arrhythmias, Cardiac
Interventions: CanGaroo Envelope; Device
Lead sponsor: Elutia Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 23
States / cities: Little Rock, Arkansas • Daytona Beach, Florida • Delray Beach, Florida + 20 more

Conditions: Corneal Transplantation, Corneal Graft Rejection
Interventions: LX201, Placebo; Drug · Other
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 24
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more

Conditions: Acne Vulgaris
Interventions: Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Muscle Weakness, ICU-acquired Weakness
Interventions: HMB protein supplement (3g), Nutritional Supplement; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Geographic Atrophy, Age-related Macular Degeneration
Interventions: RO7669330, Syfovre™, Izervay™; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 55 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 17
States / cities: Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 14 more

Conditions: Solid Tumors, Advanced Solid Tumors
Interventions: EP-100; Drug
Lead sponsor: Esperance Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Scottsdale, Arizona

Conditions: Pancreatic Necrosis
Interventions: AXIOS™ stent, Double Pigtail Stents; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Pharmacokinetics After Oral Intake
Interventions: sulopenem etzadroxil and probenecid; Drug
Lead sponsor: Iterum Therapeutics, International Limited; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
Interventions: edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 8,292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 82
States / cities: Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more

Conditions: Acne Vulgaris
Interventions: Sarecycline; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 9 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 56
States / cities: Mobile, Alabama • Hot Springs, Arkansas • Carlsbad, California + 46 more

Conditions: Acute Kidney Injury
Interventions: Niyad (nafamostat mesylate), Placebo (0.9% NaCl); Device
Lead sponsor: Talphera, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Orlando, Florida • Detroit, Michigan + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol; Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 12
States / cities: Palm Desert, California • Pasadena, California • Santa Maria, California + 9 more

Conditions: Wound
Interventions: 3M™ V.A.C.® Peel and Place Dressing; Device
Lead sponsor: Solventum US LLC; Industry
Eligibility: 22 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Indianapolis, Indiana • St Louis, Missouri • Bethlehem, Pennsylvania

Conditions: Ulcerative Colitis
Interventions: Budesonide MMX 6 mg Tablet, Placebo Tablet; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 53
States / cities: Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 46 more

Conditions: Glaucoma
Interventions: Trabeculectomy, Ex-PRESS mini shunt; Procedure · Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 7
States / cities: San Francisco, California • Gainesville, Florida • St Louis, Missouri + 4 more

Conditions: Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
Interventions: Apremilast; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Portland, Oregon + 1 more

Conditions: Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor, Multiple System Atrophy, Drug Induced Parkinson's Disease, Diffuse Lewy Body Disease, Myasthenia Gravis, Spinal Cord Injuries
Interventions: Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation, Peripheral Nerve Stimulation; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Coronary Artery Disease
Interventions: Clopidogrel & Aspirin, Prasugrel & Aspirin, Placebo & Aspirin; Drug
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 2,509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
Interventions: Bevacizumab, Optune, Brain MRI, Quality of Life Questionnaires; Drug · Device · Other
Lead sponsor: University of Florida; Other
Eligibility: 22 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Gainesville, Florida • St Louis, Missouri

Conditions: Femoral Neck Fractures, Intertrochanteric Fracture
Interventions: Gamma3 Intramedullary Nails (Stryker), Sliding Hip Screws; Procedure
Lead sponsor: Stryker Trauma and Extremities; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 7
States / cities: Fresno, California • San Francisco, California • Boston, Massachusetts + 4 more

Conditions: Parkinson Disease
Interventions: multilimb dual task; Other
Lead sponsor: A.T. Still University of Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Liposarcoma, Dedifferentiated
Interventions: Brigimadlin, Doxorubicin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 16 more

Conditions: Anemia
Interventions: Not listed
Lead sponsor: Convergence Biometrics; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Belatacept Conversion in Proteinuric Kidney Transplant Recipients

CanGaroo® Registry Study

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

Improving Muscle Function in Nutritionally at Risk, Elderly Patients

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors

Study of a Lumen- Apposing, Covered, Self-Expanding Metal Stent (Axios™) Versus Multiple Double Pigtail Stents

Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing

(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.

Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

Biomarkers in Neural Disorders

CYPRESS - CYPHER for Evaluating Sustained Safety

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

Intramedullary Nail Versus Sliding Hip Screw Inter-Trochanteric Evaluation

Multi-limb Dual-task Control in Parkinson's Disease

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Non-Invasive Hemoglobin Study